AstraZeneca PLC (AZN) - Net Assets
Based on the latest financial reports, AstraZeneca PLC (AZN) has net assets worth $48.72 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($114.07 Billion) and total liabilities ($65.36 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AZN total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $48.72 Billion |
| % of Total Assets | 42.71% |
| Annual Growth Rate | 12.97% |
| 5-Year Change | 24.01% |
| 10-Year Change | 192.27% |
| Growth Volatility | 212.89 |
AstraZeneca PLC - Net Assets Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see how much is AstraZeneca PLC worth.
Annual Net Assets for AstraZeneca PLC (1990–2025)
The table below shows the annual net assets of AstraZeneca PLC from 1990 to 2025. Explore how efficiently does AstraZeneca PLC generate cash to assess how effectively this company generates cash.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $48.72 Billion | +19.20% |
| 2024-12-31 | $40.87 Billion | +4.35% |
| 2023-12-31 | $39.17 Billion | +5.69% |
| 2022-12-31 | $37.06 Billion | -5.67% |
| 2021-12-31 | $39.29 Billion | +151.23% |
| 2020-12-31 | $15.64 Billion | +7.14% |
| 2019-12-31 | $14.60 Billion | +3.93% |
| 2018-12-31 | $14.04 Billion | -15.61% |
| 2017-12-31 | $16.64 Billion | -0.16% |
| 2016-12-31 | $16.67 Billion | -9.94% |
| 2015-12-31 | $18.51 Billion | -5.79% |
| 2014-12-31 | $19.65 Billion | -15.51% |
| 2013-12-31 | $23.25 Billion | -2.92% |
| 2012-12-31 | $23.95 Billion | +2.04% |
| 2011-12-31 | $23.47 Billion | +0.26% |
| 2010-12-31 | $23.41 Billion | +12.43% |
| 2009-12-31 | $20.82 Billion | +29.65% |
| 2008-12-31 | $16.06 Billion | +7.68% |
| 2007-12-31 | $14.91 Billion | -3.25% |
| 2006-12-31 | $15.42 Billion | +12.60% |
| 2005-12-31 | $13.69 Billion | -5.56% |
| 2004-12-31 | $14.50 Billion | +9.35% |
| 2003-12-31 | $13.26 Billion | +18.09% |
| 2002-12-31 | $11.23 Billion | -18.43% |
| 2001-12-31 | $13.76 Billion | +44.13% |
| 2000-12-31 | $9.55 Billion | -7.63% |
| 1999-12-31 | $10.34 Billion | +144.60% |
| 1998-12-31 | $4.23 Billion | +16.63% |
| 1997-12-31 | $3.62 Billion | -1.03% |
| 1996-12-31 | $3.66 Billion | +20.58% |
| 1995-12-31 | $3.04 Billion | +11.42% |
| 1994-12-31 | $2.73 Billion | +17.26% |
| 1993-12-31 | $2.32 Billion | +1268.01% |
| 1992-12-31 | $169.87 Million | -81.47% |
| 1991-12-31 | $916.88 Million | +34.27% |
| 1990-12-31 | $682.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AstraZeneca PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1821.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $10.97 Billion | 22.55% |
| Common Stock | $388.00 Million | 0.80% |
| Other Comprehensive Income | $2.04 Billion | 4.19% |
| Other Components | $35.27 Billion | 72.46% |
| Total Equity | $48.67 Billion | 100.00% |
AstraZeneca PLC Competitors by Market Cap
The table below lists competitors of AstraZeneca PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AstraZeneca PLC
MX:AZNN
|
$290.50 Billion |
|
Morgan Stanley
SA:MSBR34
|
$293.89 Billion |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
$293.92 Billion |
|
GE Aerospace
NYSE:GE
|
$304.08 Billion |
|
PetroChina Co Ltd Class A
SHG:601857
|
$289.54 Billion |
|
General Electric Company
SA:GEOO34
|
$289.12 Billion |
|
Lam Research Corp
NASDAQ:LRCX
|
$287.98 Billion |
|
Novartis AG
MX:NVSN
|
$285.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AstraZeneca PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 40,786,000,000 to 48,667,000,000, a change of 7,881,000,000 (19.3%).
- Net income of 10,255,000,000 contributed positively to equity growth.
- Dividend payments of 5,081,555,000 reduced retained earnings.
- Share repurchases of 719,657,000 reduced equity.
- Other comprehensive income increased equity by 2,041,000,000.
- Other factors increased equity by 1,867,212,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $10.26 Billion | +21.07% |
| Dividends Paid | $5.08 Billion | -10.44% |
| Share Repurchases | $719.66 Million | -1.48% |
| Other Comprehensive Income | $2.04 Billion | +4.19% |
| Other Changes | $1.87 Billion | +3.84% |
| Total Change | $- | 19.32% |
Book Value vs Market Value Analysis
This analysis compares AstraZeneca PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 117.58x to 3.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $1.59 | $187.37 | x |
| 1991-12-31 | $2.18 | $187.37 | x |
| 1992-12-31 | $0.23 | $187.37 | x |
| 1993-12-31 | $5.22 | $187.37 | x |
| 1994-12-31 | $5.57 | $187.37 | x |
| 1995-12-31 | $6.08 | $187.37 | x |
| 1996-12-31 | $7.36 | $187.37 | x |
| 1997-12-31 | $7.51 | $187.37 | x |
| 1998-12-31 | $8.94 | $187.37 | x |
| 1999-12-31 | $11.60 | $187.37 | x |
| 2000-12-31 | $10.78 | $187.37 | x |
| 2001-12-31 | $15.60 | $187.37 | x |
| 2002-12-31 | $12.88 | $187.37 | x |
| 2003-12-31 | $15.42 | $187.37 | x |
| 2004-12-31 | $17.22 | $187.37 | x |
| 2005-12-31 | $16.81 | $187.37 | x |
| 2006-12-31 | $19.50 | $187.37 | x |
| 2007-12-31 | $19.73 | $187.37 | x |
| 2008-12-31 | $21.90 | $187.37 | x |
| 2009-12-31 | $28.50 | $187.37 | x |
| 2010-12-31 | $32.11 | $187.37 | x |
| 2011-12-31 | $34.01 | $187.37 | x |
| 2012-12-31 | $37.56 | $187.37 | x |
| 2013-12-31 | $37.04 | $187.37 | x |
| 2014-12-31 | $31.06 | $187.37 | x |
| 2015-12-31 | $29.23 | $187.37 | x |
| 2016-12-31 | $23.47 | $187.37 | x |
| 2017-12-31 | $23.61 | $187.37 | x |
| 2018-12-31 | $19.68 | $187.37 | x |
| 2019-12-31 | $20.18 | $187.37 | x |
| 2020-12-31 | $23.80 | $187.37 | x |
| 2021-12-31 | $55.04 | $187.37 | x |
| 2022-12-31 | $47.48 | $187.37 | x |
| 2023-12-31 | $50.12 | $187.37 | x |
| 2024-12-31 | $52.19 | $187.37 | x |
| 2025-12-31 | $62.31 | $187.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AstraZeneca PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.46%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 2.34x
- Recent ROE (21.07%) is below the historical average (30.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | 75.00% | 5.83% | 1.20x | 10.69x | $371.13 Million |
| 1991 | 82.54% | 8.78% | 1.16x | 8.13x | $567.34 Million |
| 1992 | 145.45% | 2.01% | 0.98x | 74.18x | $112.99 Million |
| 1993 | 28.75% | 9.71% | 0.88x | 3.35x | $415.80 Million |
| 1994 | 26.29% | 9.89% | 0.96x | 2.78x | $429.15 Million |
| 1995 | 18.05% | 6.86% | 0.96x | 2.74x | $231.63 Million |
| 1996 | 31.61% | 11.99% | 1.07x | 2.46x | $752.82 Million |
| 1997 | 33.80% | 14.05% | 1.04x | 2.32x | $849.70 Million |
| 1998 | 28.40% | 10.47% | 1.26x | 2.15x | $767.86 Million |
| 1999 | 11.09% | 7.55% | 0.76x | 1.92x | $112.74 Million |
| 2000 | 26.67% | 14.02% | 0.98x | 1.94x | $1.59 Billion |
| 2001 | 30.31% | 25.22% | 0.62x | 1.93x | $2.79 Billion |
| 2002 | 25.40% | 15.90% | 0.83x | 1.93x | $1.72 Billion |
| 2003 | 23.04% | 16.11% | 0.80x | 1.79x | $1.72 Billion |
| 2004 | 25.44% | 17.10% | 0.84x | 1.78x | $2.22 Billion |
| 2005 | 34.61% | 19.65% | 0.96x | 1.83x | $3.35 Billion |
| 2006 | 39.49% | 22.83% | 0.88x | 1.96x | $4.51 Billion |
| 2007 | 37.86% | 18.93% | 0.62x | 3.25x | $4.12 Billion |
| 2008 | 38.34% | 19.31% | 0.67x | 2.95x | $4.51 Billion |
| 2009 | 36.40% | 22.93% | 0.60x | 2.66x | $5.46 Billion |
| 2010 | 34.69% | 24.21% | 0.59x | 2.42x | $5.73 Billion |
| 2011 | 42.66% | 29.52% | 0.64x | 2.27x | $7.59 Billion |
| 2012 | 26.29% | 22.31% | 0.52x | 2.26x | $3.87 Billion |
| 2013 | 11.01% | 9.90% | 0.46x | 2.41x | $233.60 Million |
| 2014 | 6.28% | 4.64% | 0.45x | 2.99x | $-729.70 Million |
| 2015 | 15.28% | 11.43% | 0.41x | 3.25x | $976.00 Million |
| 2016 | 23.56% | 15.21% | 0.37x | 4.21x | $2.01 Billion |
| 2017 | 20.06% | 13.36% | 0.35x | 4.23x | $1.50 Billion |
| 2018 | 17.28% | 9.76% | 0.36x | 4.86x | $908.20 Million |
| 2019 | 10.17% | 5.47% | 0.40x | 4.68x | $22.30 Million |
| 2020 | 20.46% | 12.01% | 0.40x | 4.27x | $1.63 Billion |
| 2021 | 0.29% | 0.30% | 0.36x | 2.68x | $-3.81 Billion |
| 2022 | 8.88% | 7.41% | 0.46x | 2.61x | $-415.70 Million |
| 2023 | 15.21% | 13.00% | 0.45x | 2.58x | $2.04 Billion |
| 2024 | 17.25% | 13.01% | 0.52x | 2.55x | $2.96 Billion |
| 2025 | 21.07% | 17.46% | 0.51x | 2.34x | $5.39 Billion |
Industry Comparison
This section compares AstraZeneca PLC's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $11,870,068,444
- Average return on equity (ROE) among peers: 20.61%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $48.72 Billion | 75.00% | 1.34x | $290.48 Billion |
| AbbVie Inc (ABBV) | $-8.17 Billion | 0.00% | 0.00x | $373.65 Billion |
| Amgen Inc (AMGN) | $19.03 Billion | 19.35% | 1.57x | $186.63 Billion |
| Amarin Corporation PLC (AMRN) | $595.33 Million | -17.77% | 0.49x | $289.80 Million |
| Biogen Inc (BIIB) | $68.00 Million | -1.76% | 0.19x | $27.74 Billion |
| Bristol-Myers Squibb Company (BMY) | $31.12 Billion | 20.33% | 2.11x | $123.35 Billion |
| Gilead Sciences Inc (GILD) | $4.47 Billion | 44.31% | 0.55x | $162.33 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $2.77 Billion | 66.33% | 2.38x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $39.32 Billion | 28.11% | 0.79x | $553.78 Billion |
| Eli Lilly and Company (LLY) | $17.64 Billion | 26.56% | 1.00x | $836.48 Billion |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more